Originally posted by aslyfox Other companies produce it as well. I get a "generic" version from Wegman's and it's pretty inexpensive, as drugs go. If Novartis is successful in developing some good data, and the FDA manages to approve the use, they'll be one of many producing what is already a fairly cheap and available drug. I doubt that Novartis is going to get rich off this drug, and commend them for their efforts.
The one thing I worry about is the failure to distinguish between the two types of death arising from the virus. Those with weakened immune systems get sick and die because they lack the ability to fight off the virus; those with strong immune systems (people with autoimmune disorder and young adults) die because their immune systems react too quickly and strongly causing a flood of fluid in the lungs.
The reason that's important is that hydroxychloroquine (and quinone group chemicals like "tonic water") suppress the immune systems' ability to produce certain leukocytes ("white blood cells") responsible for identification of the "foreign protein" so that the body can create "killer T-cells" (another kind of leukocyte) to go eat the intruders. I.e., an immunosuppressant. Give that stuff to old people and children (people with weaker immune systems) not only won't do any good against this virus, it will interfere with what little defense they've got. People with strong immune systems should take it upon identification of the virus in their bodies, because it will prevent the "cytokine storm" that causes pneumonia.
And, by the way, with respect to the testing issue, there was a reference to "nosocomial infections" - that's a code phrase for "diseases caused by having been in a hospital"; a concept similar to "iatrogenic infections", which are "diseases that are caused by having had contact with a physician".